Close Menu

IVF

By Justin Petrone
British array firm BlueGnome this month relocated to new headquarters to keep pace with growth that has seen it double most of activities in the past year.

Cambridge, UK-based BlueGnome made the acquisition to carve out a bigger piece of the pre-implantation, genetic-diagnostic market. The firm "aims to address diagnosis of single-gene disorders using SNP-array technology," according to its CEO.

The new firm, founded to take advantage of a "rapidly growing" market for pre-implantation genetic screening services, will directly offer BlueGnome's 24Sure platform to in vitro fertilization centers in Europe.

The results not only have the potential to improve the chances of pregnancy for couples undergoing IVF, but also point toward opportunities for research and diagnostic testing of single cancer cells and stem cells, according to a Rubicon official.

The company will use the money to accelerate the global launch of its metabolomics-based procedure for enhancing in vitro fertilization outcomes.

Pages

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.